Urovant Sciences Ltd (NASDAQ:UROV) Q4 2018 Earnings Conference Call - Final Transcript
Jun 13, 2019 • 04:30 pm ET
Thank you. (Operator Instructions) Our first question comes from the line of Biren Amin of Jefferies. Your line is open.
Hi, guys. This is Jeet on for Biren. Thanks for taking our question. Just wanted to know if you could provide any additional color on physician and payer feedback following the EMPOWUR readout and what data points might have spill out in particular to them compared to mirabegron? Thanks.
Yes. So we conducted a qualitative market research of 42 physicians, both thought leaders and prescribing physicians and reviewed the topline data with them. They also were aware -- these physicians were aware of other products in the market and what their data was in the context of that research. And the physician feedback was very clear. They felt that the product if approved will represent a clear choice versus Myrbetriq and I believe it already would represent a clear choice versus anticholinergic.
And I think the attributes that were called out by the physicians is most impactful were 2-week onset versus Myrbetriq's 8-week onset. They also -- physicians commented that the UUI data, volume voided data, urgency and responder secondary endpoints were key differentiators and were represented really robust efficacy numbers. Additionally, the safety profile was viewed as favorable by those physicians. And last but not least, they commented that any drug that does not require titration, single dose and starting dose is preferable for their practice.
Okay. Thank you.
Thank you. Our next question comes from Edward Nash of SunTrust. Your line is open.
Hi. This is (inaudible) on for Edward. Did you have any early discussion with payers with regard to how vibegron is likely going to be reimbursed?
So we completed an initial payer research last summer. We did that with two different payer research studies, both of which came back with the exact same output from the study. They represent over 160 million payer lives in the US both commercial and Medicare D.
And the payers shared with -- they offer that research was really threefold: One, they don't view the class as one that they highly manage or regulate, they view it as very predictable for their auctorial models to manage and price the class for employers and patients; and third, they manage the class with co-pay differential today and will continue to do so in the future meaning that if a patient chooses to fill a branded script, they prefer to differentiate the branded script from a generic with co-pay differential.
They don't actively manage the class with prior authorizations or stuff added, and we believe that is due to the pricing of the class and the predictability of the class. And indeed, we've quantified that the results of that research by looking at how drugs in the class are covered and they are covered with no restriction in over 90% of covered lives. And that includes Myrbetriq, it included and it includes (inaudible). So the payers are telling us pre-open class relative to many